Last updated: May 25, 2026
Doxorubicin hydrochloride is supplied globally by multiple drug-substance (API) and finished-dose manufacturers, spanning brand and generic channels. The supplier landscape is split between (1) sterile injectable manufacturing for the finished dosage form and (2) chemical synthesis for the active pharmaceutical ingredient.
Who supplies doxorubicin hydrochloride API (drug substance)?
Featured snippet:
Common API supply channels include global sterile-and-API manufacturers in China/India and Western chemical producers that sell doxorubicin hydrochloride under contracts to injectables formulators and sterile product companies.
Typical API supplier profiles
- API-only producers that sell doxorubicin hydrochloride to injectable manufacturers.
- Vertical integrators that produce doxorubicin hydrochloride and also supply sterile products.
- Contract manufacturers supporting supply continuity for shortages and tender-driven procurement.
What to look for in API supplier due diligence
- Regulatory status (FDA DMF holder where applicable, and inspection history).
- API polymorph/grade control and impurity profile (notably residual solvents, related substances).
- Ability to support sterile drug product manufacturing with consistent spec and traceability.
Who supplies doxorubicin hydrochloride injection (finished dosage form)?
Featured snippet:
Finished doxorubicin hydrochloride injection is supplied by generic injectable manufacturers and license/contract sterile facilities that fill vials or bottles under cGMP sterile manufacturing and distribution networks.
Finished product supplier categories
- US generic injectable manufacturers for 2 mg/mL (and other commonly marketed strengths) vial presentations.
- Hospital channel suppliers through group purchasing organizations and oncology product distributors.
- Multi-source suppliers that compete on price, tender terms, and supply reliability.
Labeling and presentation variants that affect sourcing
- Strength and pack size (single-dose vials vs multi-pack cartons).
- Concentration format (commonly 2 mg/mL, plus other strengths depending on market).
- Packaging materials and labeling requirements by jurisdiction.
How many qualified suppliers exist for doxorubicin hydrochloride globally?
Featured snippet:
There are multiple qualified suppliers worldwide, but the active pool narrows in practice when you segment by (a) US-qualified sterile injectables, (b) API DMF availability, and (c) production slot capacity.
Practical count categories (procurement reality)
- API market: larger number of chemical producers, but fewer with stable regulatory and quality documentation for Western sterile programs.
- Finished injectables market: fewer because sterile filling is capacity- and aseptic-operations constrained.
Which companies are major suppliers of doxorubicin hydrochloride in the US?
Featured snippet:
In the US market, supplier competition is driven by generic sterile manufacturers that have established injection-vial capacity and distribution.
US procurement patterns
- Hospitals typically source through distributors with standing supply agreements.
- Procurement tends to consolidate with suppliers that can match tender timelines and maintain stock during oncology supply shocks.
Which companies supply doxorubicin hydrochloride outside the US (EU, UK, APAC)?
Featured snippet:
EU/UK and APAC supply relies on regionally licensed generic injectable manufacturers plus API producers with dossiers that support local marketing authorizations.
Regulatory drivers by region
- EU relies on local marketing authorizations and batch release under EU GMP frameworks.
- UK follows MHRA licensing pathways for authorized products.
- APAC supply often uses region-specific registration, labeling, and packaging controls.
What is the Orange Book status of doxorubicin hydrochloride products?
Featured snippet:
Doxorubicin hydrochloride is an established generic oncology drug and is not typically tied to single-product exclusivity in the same way as newer molecular entities; supply is dominated by multiple approved ANDA products.
What that means for supplier selection
- A competitive field of approved generic SKUs exists.
- Supplier differentiation shifts to manufacturing reliability, supply continuity, and batch-to-batch consistency.
What patents protect doxorubicin hydrochloride, and does that constrain suppliers?
Featured snippet:
The active ingredient doxorubicin hydrochloride is an established compound; IP constraints today typically do not function as a broad barrier to generic supply of the core API, but specific product-line IP may exist around formulation, packaging, or manufacturing process for particular presentations.
Where IP can still matter
- Process patents for impurity control or manufacturing steps.
- Formulation patents for concentration/solubility/sterility stability for a specific vial strength.
- Method-of-use patents tied to combination regimens or dosing schedules for specific indications (less common for the core drug substance).
How do doxorubicin hydrochloride shortage events change the supplier list?
Featured snippet:
During oncology injectable shortages, the effective supplier list contracts to the fastest-qualified and highest-capacity sterile fillers, even if more API vendors exist.
Shortage mechanics
- API supply continuity becomes the gating item for injectable manufacturers.
- Sterile filling slots and QC release timelines create bottlenecks.
- Distributors prioritize continuity contracts and substitutable SKUs by concentration and pack configuration.
What generic entry risks exist for doxorubicin hydrochloride injectables?
Featured snippet:
The major risks are operational rather than patent-driven: aseptic manufacturing qualification delays, release testing capacity, and API consistency.
Common barriers
- Sterile manufacturing validation and media fill timelines.
- Stability, container closure integrity, and leachables extractables testing.
- Batch release bottlenecks during surges in demand.
Which formulations are protected by suppliers’ product-line IP (vial strengths, concentrations)?
Featured snippet:
Product-line IP, when present, tends to be tied to specific vial strengths and manufacturing controls rather than the universal chemical entity doxorubicin hydrochloride.
Formulation variables that influence IP and supplier spec
- Target concentration and allowable pH range.
- Stabilizers and excipient sets (if any per specific label).
- Container closure system and compatibility.
How does doxorubicin hydrochloride compare with liposomal doxorubicin (that can change supplier strategy)?
Featured snippet:
Liposome-encapsulated doxorubicin (e.g., Doxil-related products) is a different manufacturing and IP landscape; it is not a substitute at the interchangeability level for all oncology protocols, so supplier risk management often treats them separately.
Implication for procurement
- If the conventional doxorubicin hydrochloride supply tightens, some health systems switch to protocol-appropriate alternatives, but not universally.
- Supplier planning must account for clinical substitution constraints and separate manufacturing pipelines.
Commercial implications: how supplier availability affects oncology procurement
Featured snippet:
For doxorubicin hydrochloride, price and availability are strongly linked to sterile manufacturing throughput, API continuity, and batch release capacity rather than to patent exclusivity.
Procurement levers
- Multi-source tendering across vial strengths and pack sizes that are clinically substitutable.
- Safety stock planning using lead-time forecasts for sterile release.
- Contract terms that cover allocation and contingency supply.
Key Takeaways
- Doxorubicin hydrochloride supply is split between API producers and sterile injectable finished-dose manufacturers.
- Patent-driven supply constraints are less likely to be the primary limiter for the core API; operational capacity and sterile manufacturing readiness drive availability.
- Shortage dynamics shrink the effective supplier list to those with the strongest sterile filling and batch release capacity.
- Supplier due diligence should prioritize regulatory documentation, impurity/spec control, aseptic manufacturing validation status, and container closure compatibility.
FAQs
Which manufacturers produce doxorubicin hydrochloride injection in vials?
Manufacturers that supply generic sterile injectables via US/EU marketing authorizations produce doxorubicin hydrochloride in vial presentations as licensed strengths and pack configurations.
Can doxorubicin hydrochloride be sourced from multiple API suppliers without regulatory friction?
Yes, but the finished-dose manufacturer’s regulatory strategy and comparability requirements for the labeled product determine whether alternate API sources can be qualified smoothly.
Does liposomal doxorubicin replace doxorubicin hydrochloride for procurement continuity?
Not always. Clinical protocol constraints and product differences mean substitution is limited and protocol-dependent.
What drives lead times for doxorubicin hydrochloride injection?
Aseptic filling scheduling, QC release capacity, and API batch availability are typically the lead-time drivers.
What is the main quality risk in doxorubicin hydrochloride supply chains?
Batch-to-batch impurity profile and consistency of critical parameters in sterile manufacturing, including container closure compatibility and stability under labeled storage conditions.
References (APA)
- FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA. (n.d.). Drug Shortages. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-shortages
- EMA. (n.d.). EU Medicines. European Medicines Agency. https://www.ema.europa.eu/en/medicines
